帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Pretreatment nutritional status, HPV infection, and tumor infiltrating lymphocyte as prognostic predictors in patients with head and neck squamous cell carcinoma after chemotherapy.
Pretreatment nutritional status, HPV infection, and tumor infiltrating lymphocyte as prognostic predictors in patients with head and neck squamous cell carcinoma after chemotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在 HNSCC 患者中,体重不足与显著更高的疾病进展风险相关,且往往总生存期更短。
头颈癌的生存率因亚型而异,但不同研究中与生存相关的因素仍存在争议。本研究旨在调查治疗前营养状况、人乳头瘤病毒(HPV)感染、TIL(肿瘤浸润淋巴细胞)与印度尼西亚头颈部鳞状细胞癌(HNSCC)患者化疗后治疗应答之间的关联,并评估与总生存期相关的因素。
这是一项回顾性队列研究,数据收集时间为2015年1月至2018年1月。纳入30例经组织病理学确诊、至少接受3个疗程化疗的头颈部鳞状细胞癌患者。使用体重指数(BMI)评估营养状况。
平均BMI为21.8 kg/m²(标准差3.98)。与BMI较高者相比,体重过轻患者发生疾病进展的风险较高(OR=12.1,95% CI:1.1–135.6,P=0.04)。HPV感染和TIL均与治疗应答或总生存期无关(P>0.05)。体重过轻患者中位生存期为9个月(95% CI:3.00–15.00),而正常体重和肥胖患者为14个月(95% CI:9.33–18.67)。
体重过轻与HNSCC患者疾病进展风险显著升高相关,并呈现总生存期较短的趋势。但HPV感染和TIL均与治疗应答和总生存期无关。
The survival rate in head and neck cancer varies among the subtypes, yet, the factors associated with survival between studies are still conflicting. This study aimed to investigate the association between pretreatment nutritional status, human papilloma virus (HPV) infection, tumor infiltrating lymphocyte (TIL), and treatment response after chemotherapy in patients with head and neck squamous cell carcinoma (HNSCC) in Indonesia. Further, factors associated with overall survival were also assessed.
This was a retrospective cohort study. Data were collected between January 2015 and January 2018. A total of 30 patients with histopathologically proven squamous cell carcinoma head and neck cancer who had received at least three cycles of chemotherapy were included. Nutritional status was assessed using body mass index (BMI).
The mean BMI was 21.8 kg/m 2 (Standard Deviation 3.98). The underweight patients had a higher risk of progressive disease (OR = 12.1, 95% CI = 1.1-135.6, P = 0.04) compared to patients with higher BMI. Neither HPV infection nor TIL was associated with treatment response and overall survival (P > 0.05). The median survival for the underweight patients was 9 months (95% CI = 3.00-15.00), whereas the median survival for normal and obese patients was 14 months (95% CI = 9.33-18.67).
Underweight is associated with a significantly higher risk of progressive disease and tends to have shorter overall survival in patients with HNSCC. Yet, neither HPV infection nor TIL was associated with treatment response and overall survival.
MEMBER ACCOUNT
登录成功会直接打开下一页。